The recent dismissal of 13 FDA review staff eliminated precisely the kind of government spending that delivered the most bang ...

At CTO West Coast, an expert discussed the implications of the FDA’s expedited approval programmes with a spotlight on ...

Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

Successful drug development for bioactive lipid targets requires a deep knowledge of the biology and pathobiology of each specific lipid signaling pathway. Successful development of drugs for ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...

Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.

As AI transforms medicine, some of the most promising healthcare innovations are at risk of exclusion by Medicare’s outdated and complex ...

we must all shift our way of thinking and bring these discussions back to our organisations to ensure that we are well poised to deal with changes in the drug development pathway, and that we ...

While cohort A met the primary endpoint among other endpoints in the Phase II trial, cohort B failed to meet its primary ...

Figure 5: Pathways of lipid absorption and pooling ... and an overall increase in the complexity (perceived or otherwise) of the drug development programme. Nonetheless, in situations in which ...

I would argue not. The current drug development pathway for rare diseases is not sustainable, either in terms of addressing the high unmet therapeutic needs of patients through ensuring rapid ...

Rett syndrome market dynamics are expected to undergo significant shifts as more targeted therapies, including gene therapies and pharmacological interventions, enter clinical development and ...